Drug Profile
Research programme: paclitaxel nanoparticle - LipoMedics
Alternative Names: LM-101; LM-102; LM-201; LM-301Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator LipoMedics
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral, Injection)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in USA (Parenteral)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)